Skip to content

A pair of antibodies keeps HIV undetectable by ‘bolting the door and masking the key’

Dr Martin Markowitz at HIV Glasgow 2026. He is standing behind a lectern.

“Normal is the perfect word”: participants describe switching to weekly HIV treatment

Professor Chloe Orkin at HIV Glasgow 2026.

From “good news” to “failure”: how French participants experienced an HIV remission trial

A man talks to a healthcare professional.

'We finally understand what we have to do': antibody studies point the way to an HIV cure

A scientist works in a lab.

Lean people with HIV can still develop fatty liver disease

Florence Bascombe at AIDS 2026. She is standing at a lectern, talking into a microphone.

Returning to HIV care does not erase the effects of treatment interruption, studies show

Sanele Mbeje at AIDS 2026. He is standing at a lectern, behind a laptop, talking into a microphone.

Alternative first-line HIV regimen limits excess weight gain

Dr Joana Woods at AIDS 2026. She is talking into a microphone with a laptop screen in front of her.

Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression

Dr Amy Colson at AIDS 2026. She is talking into a microphone with a screen behind her.

Islatravir plus ulonivirine shows promise for weekly oral HIV treatment

A person holds a blue pill in their hand and a glass of water.